PFIZER

March 19 (Reuters) - Pfizer Ltd PFIZ.NS:

• LIC CUTS STAKE IN PFIZER TO 4.026% FROM 6.052% - EXCHANGE FILING

Source text: ID:nBSEbtwH6P

Further company coverage: PFIZ.NS

(([email protected];))

Jan 31 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER DEC-QUARTER NET PROFIT 1.28 BILLION RUPEES

• PFIZER DEC-QUARTER REVENUE FROM OPERATIONS 5.38 BILLION RUPEES

Source text: ID:nBSE5kQk0R

Further company coverage: PFIZ.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees

** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking

** INRM last up about 2%, set to snap nine-session losing streak

** Stock still down ~22% so far this year, on track for third straight year of losses

** YTD, peers Pfizer Ltd PFIZ.NS and Ajanta Pharma AJPH.NS up ~20% and ~43%, respectively

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 28 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD SEPT-QUARTER NET PROFIT 1.58 BILLION RUPEES

• PFIZER LTD SEPT-QUARTER REVENUE FROM OPERATIONS 5.89 BILLION RUPEES

Source text: [ID:]

Further company coverage: PFIZ.NS

(([email protected];))

Oct 8 (Reuters) - Pfizer PFE.N CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

(([email protected];))

Oct 6 (Reuters) - Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer PFE.N and wants the U.S. drug giant to make changes to turn its performance around, the Wall Street Journal reported on Sunday.

(Reporting by Surbhi Misra in Bengaluru; Editing by Tom Hogue)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

** Shares of Pfizer Ltd PFIZ.NS, Indian unit of pharma firm Pfizer Inc PFE.N, up as much as 5.3% at 5,651.3 rupees, highest since Oct 2021

** Co's June-qtr profit up ~61% YoY, revenue rises 5.9%

** Analysts' rating on PFIZ, on avg, is "hold", PT is 4,797.50 rupees - LSEG data

** PFIZ eyes second biggest monthly rise since Oct 2021

** Stock up ~29% YTD, on track for a second straight session of gains

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected]))

July 29 (Reuters) - Pfizer Ltd PFIZ.NS:

• JUNE-QUARTER NET PROFIT 1.51 BILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 5.63 BILLION RUPEES

Further company coverage: PFIZ.NS

(([email protected];))

May 17 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD - DIVIDEND 35 RUPEESPER SHARE

• PFIZER LTD MARCH-QUARTER NET PROFIT 1.79 BILLION RUPEES VERSUS PROFIT 1.3 BILLION RUPEES

• PFIZER LTD MARCH-QUARTER REVENUE FROM OPERATIONS 5.47 BILLION RUPEES VERSUS 5.73 BILLION RUPEES

Source text for Eikon: ID:nNSEb7YxzX

Further company coverage: PFIZ.NS

(([email protected];;))

** Shares of Pfizer Ltd PFIZ.NS, Indian unit of Pfizer Inc PFE.N, down 3.7% at 4,347.85 rupees

** Stock on track for worst day since Feb. 13, 2023, and to fall for a third straight session

** Co's Q3 profit fell ~14% YoY

** Rivals Abbott India ABOT.NS and GlaxoSmithKline Pharma GLAX.NS posted higher Q3 profits, sending shares up

** Avg analyst rating on PFIZ is "strong buy", GLAX rated "hold" and ABOT rated "buy" - LSEG data

** PFIZ's avg PT is 4,519.83 rupees - LSEG data

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Jan 22 (Reuters) - Pfizer Ltd PFIZ.NS:

• NAMES AMIT AGARWAL AS CFO

Source text for Eikon: ID:nBSE1rg98y

Further company coverage: PFIZ.NS

(([email protected];))

Dec 26 (Reuters) - Pfizer Ltd PFIZ.NS:

• GOT ORDER FROM DEPUTY COMMISSIONER FOR TAX

• TOTAL DEMAND OF 16.7 MILLION RUPEES

• GOT ONE MORE ORDER FROM CGST & CX FOR DEMAND OF 7.7 MILLION RUPEES

Further company coverage: PFIZ.NS

(([email protected];))

** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed

** Volumes in November down 4.5% year-on-year after rising 5% in the previous month

** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November

** Eris Lifesciences ERIS.NS, Cipla CIPL.NS, Torrent Pharmaceuticals TORP.NS, Sun Pharmaceutical Industries SUN.NS and Glenmark Pharmaceuticals GLEN.NS see sales uptick of 7% to 11%, outperforming the Indian pharma market

** FDC FDC.NS, Alembic Pharma ALEM.NS, GlaxoSmithKline Pharmaceuticals GLAX.NS and Mankind Pharma MNKI.NS underperform the industry, in terms of November sales

** Pfizer PFIZ.NS sees sales decline of 11.9% while Sanofi India SANO.NS posts 5.7% monthly sales drop

** Nifty pharma index .NIPHARM down 0.9% on the day, dragged by 5% drop in Dr. Reddy's Laboratories REDY.NS on U.S. drug regulator's observations on the drug maker's facility at Hyderabad

** Pharma index up 27% in 2023 so far, compared with 16% rise in Nifty 50 index .NSEI

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 30 (Reuters) - Pfizer Ltd PFIZ.NS:

• MILIND PATIL, CHIEF FINANCIAL OFFICER OF COMPANY HAS RETIRED

Source text for Eikon: ID:nBSEbgC0Ps

Further company coverage: PFIZ.NS

(([email protected];))

Aug 16 (Reuters) - Seagen SGEN.O said on Wednesday its cancer therapy in combination with Roche's ROG.S Kadcyla helped control disease progression in a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

BENGALURU, Aug 9 (Reuters) - Abbott India ABOT.NS, the Indian arm of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 41% rise in its first-quarter profit on Wednesday, driven by strong sales in its mainstay pharmaceuticals segment.

The company, which makes pain-reliever ibuprofen under the brand name Brufen, said its profit rose to 2.90 billion rupees ($35.02 million), compared with 2.06 billion rupees a year earlier.

Revenue from operations rose 13.4% to 14.79 billion rupees for the quarter.

For further earnings highlights, click here.

KEY CONTEXT

Abbott India, for which the pharmaceutical segment is the sole revenue generator, develops and distributes over 600 products in India, including vitamins, anti-allergic drugs and consumer care.

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales.

Last month, peer GlaxoSmithKline Pharmaceuticals GLAX.NS posted an 11% rise in its first-quarter profit, helped by a steady vaccines business.

PEER COMPARISON

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

APRIL TO JUNE STOCK PERFORMANCE

-- All data from Refinitiv

-- $1 = 82.8150 Indian rupees

(Reporting by Kashish Tandon and Biplob Kumar Das in Bengaluru; Editing by Janane Venkatraman)

(([email protected];))

May 18 (Reuters) - Pfizer Ltd PFIZ.NS:

• VOLUNTARY RECALL IS LIKELY TO HAVE AN IMPACT ON THE REVENUE AND PROFITABILITY OF THE CO

• PRODUCTS RECORDED SALE OF 1.39 BILLION RUPEES FOR YEAR ENDED ON MARCH 31, 2023

Source text for Eikon: ID:nNSE4LK27R

Further company coverage: PFIZ.NS

(([email protected];;))

May 15 (Reuters) - Pfizer Ltd PFIZ.NS:

• MARCH-QUARTER NET PROFIT 1.30 BILLION RUPEES VERSUS PROFIT 1.26 BILLION RUPEES

• MARCH-QUARTER REVENUE FROM OPERATIONS 5.73 BILLION RUPEES VERSUS 5.5 BILLION RUPEES

• RECOMMENDED FINAL DIVIDEND OF RUPEES 35 PER SHARE

• RECOMMENDED SPECIAL DIVIDEND OF RUPEES 5 PER SHARE

Source text for Eikon: [ID:]

Further company coverage: PFIZ.NS

(([email protected];;))